Neogen Corporation Payments for Restructuring
Neogen Corporation (NEOG) reported Payments for Restructuring of $7.30 million for the 12-month period ending 2026-05-31, per its 10-K filed 2026-07-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-07-30
- Neogen Corporation payments for restructuring for the quarter ending 2026-05-31 was $1.00M, a 82.15% increase year-over-year.
- Neogen Corporation payments for restructuring for the quarter ending 2026-02-28 was $1.51M, a 40.60% increase year-over-year.
- Neogen Corporation payments for restructuring for the quarter ending 2025-11-30 was $3.83M.
- Neogen Corporation payments for restructuring for the quarter ending 2025-08-31 was $955.00K.
- Neogen Corporation payments for restructuring for fiscal 2026 was $7.30M, a 163.92% increase from fiscal 2025.
- Neogen Corporation payments for restructuring for fiscal 2025 was $2.77M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2026-05-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $2.51M derived: sum of 2 quarters · filed 2026-07-30 | $6.34M derived: sum of 3 quarters · filed 2026-07-30 | $7.30M 10-K · filed 2026-07-30 |
| 2026-02-28 | $1.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-04-09 | $5.34M derived: sum of 2 quarters · filed 2026-04-09 | $6.30M 10-Q · filed 2026-04-09 | $6.85M derived: sum of 4 quarters · filed 2026-04-09 |
| 2025-11-30 | $3.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-01-08 | $4.79M 10-Q · filed 2026-01-08 | $5.34M derived: sum of 3 quarters · filed 2026-01-08 | $6.41M derived: sum of 4 quarters · filed 2026-01-08 |
| 2025-08-31 | $955.00K 10-Q · filed 2025-10-09 | $1.50M derived: sum of 2 quarters · filed 2025-10-09 | $2.58M derived: sum of 3 quarters · filed 2025-10-09 | |
| 2025-05-31 | $549.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-30 | $1.62M derived: sum of 2 quarters · filed 2025-07-30 | $2.77M 10-K · filed 2025-07-30 | |
| 2025-02-28 | $1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-04-09 | $2.22M 10-Q · filed 2025-04-09 | ||
| 2024-11-30 | $1.14M 10-Q · filed 2025-01-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |